Literature DB >> 33742233

Total Margin-Controlled Excision is Superior to Standard Excision for Keratinocyte Carcinoma on the Nose: A Veterans Affairs Nested Cohort Study.

Paul R Massey1, Sameer Gupta2, Brooke E Rothstein3, Nellie Konnikov4, Meera Mahalingam5, Emily S Ruiz1,4, Chrysalyne D Schmults1, Abigail Waldman6,7.   

Abstract

BACKGROUND: Keratinocyte carcinoma (KC), including basal and squamous cell carcinoma, is the most common human malignancy. Limited real-world data have compared surgical outcome or cost between total margin-controlled excision (TMCE) and standard excision (SE), the two most common treatments for invasive KC. We compared reconstruction, margin status, and cost between TMCE and SE for KC on the nose at a Veterans Affairs (VA) healthcare system.
METHODS: Randomly selected primary KCs on the nose ≤3 cm that were confined to soft tissue, without nerve or lymphovascular invasion, and treated with SE or TMCE between 2000 and 2010, were assessed. Utilization of flap or graft reconstruction and margin status following all surgical attempts were recorded. Costs were based on Current Procedural Terminology codes standardized to 2019 Medicare payments.
RESULTS: Overall, 148 cases were included in each treatment group. Baseline characteristics were similar between groups, although SE tumor median diameter was 1 mm larger. SE was associated with increased utilization of flap or graft reconstruction (odds ratio 2.05, 95% confidence interval 1.16-3.59, p = 0.01). Positive margins were present in 24% of SEs initially and remained positive after the final recorded excision in 9% of cases. No positive final margins were noted in TMCE cases. SE cost per tumor was significantly higher than TMCE ($429.03 ± 143.55; p = 0.003).
CONCLUSIONS: Surgical management of KC with SE is associated with increased reconstruction complexity, a significant risk of positive margins, and higher cost compared with TMCE. The 23% risk of positive margins supports National Comprehensive Cancer Network guidelines for the treatment of high-risk KC with TMCE, unless delayed reconstruction is employed.

Entities:  

Year:  2021        PMID: 33742233     DOI: 10.1245/s10434-021-09604-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

1.  Recurrence rates following surgical excision of periocular basal cell carcinomas: systematic review and meta-analysis.

Authors:  Kevin Phan; Lawrence J Oh; Sourabh Goyal; Tim Rutherford; Anousha Yazdabadi
Journal:  J Dermatolog Treat       Date:  2019-12-04       Impact factor: 3.359

2.  [The Muffin technique--an alternative to Mohs' micrographic surgery].

Authors:  Matthias Möhrle; Helmut Breuninger
Journal:  J Dtsch Dermatol Ges       Date:  2006-12       Impact factor: 5.584

3.  Tissue-sparing properties of Mohs micrographic surgery for infiltrative basal cell carcinoma.

Authors:  Marloes S van Kester; Jelle J Goeman; Roel E Genders
Journal:  J Am Acad Dermatol       Date:  2019-01-31       Impact factor: 11.527

4.  Histologic control of excised tissue edges in the operative treatment of basal-cell carcinomas.

Authors:  H Breuninger
Journal:  J Dermatol Surg Oncol       Date:  1984-09

5.  Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma.

Authors:  D E Rowe; R J Carroll; C L Day
Journal:  J Dermatol Surg Oncol       Date:  1989-04

6.  Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome.

Authors:  Frank M Muller; Robert S Dawe; Harry Moseley; Colin J Fleming
Journal:  Dermatol Surg       Date:  2009-06-03       Impact factor: 3.398

7.  Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up.

Authors:  Klara Mosterd; Gertruud A M Krekels; Fred Hm Nieman; Judith U Ostertag; Brigitte A B Essers; Carmen D Dirksen; Peter M Steijlen; Anton Vermeulen; Ham Neumann; Nicole W J Kelleners-Smeets
Journal:  Lancet Oncol       Date:  2008-11-17       Impact factor: 41.316

Review 8.  Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up.

Authors:  D E Rowe; R J Carroll; C L Day
Journal:  J Dermatol Surg Oncol       Date:  1989-03

9.  Outcomes in intermediate-risk squamous cell carcinomas treated with Mohs micrographic surgery compared with wide local excision.

Authors:  David D Xiong; Brandon T Beal; Vamsi Varra; Marla Rodriguez; Hannah Cundall; Neil M Woody; Allison T Vidimos; Shlomo A Koyfman; Thomas J Knackstedt
Journal:  J Am Acad Dermatol       Date:  2019-12-27       Impact factor: 11.527

10.  Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial.

Authors:  Nicole W J Smeets; Gertruud A M Krekels; Judith U Ostertag; Brigitte A B Essers; Carmen D Dirksen; Fred H M Nieman; H A Martino Neumann
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

View more
  1 in total

1.  Cost effectiveness of melanoma in situ resection and repair by dermatology compared to non-dermatology specialties at a single institution.

Authors:  Kevin M Burningham; Kim Le; Annie He; Madeleine O'Brian; Kevin Shi; Divya Srivastava; Rajiv I Nijhawan
Journal:  Arch Dermatol Res       Date:  2022-10-21       Impact factor: 3.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.